Bilagra-M 20mg 10 Tablets

babies: not recommended for children below 12 years of age lactating mothers: inform your doctor if you are pregnant before taking this medication. pregnancy: the safety of bilastine and montelukast sodium tablets in pregnancy is unknown.
seek doctor advice before taking this medication. driving: bilastine and montelukast sodium tablets may cause drowsiness.
avoid driving while on this medication. alcohol: alcohol consumption while taking bilastine and montelukast sodium tablets may increase side effects like drowsiness.
kidney: bilastine and montelukast sodium tablets should be used with caution in patients with kidney disease. dosage adjustment is required, and regular monitoring of kidney function may be required.
seek doctor advice before using this medication. liver: bilastine and montelukast sodium tablets should be used with caution in patients with liver disease.
dosage adjustment is required, and regular monitoring of liver function may be required. seek doctor advice before using this medication.
.

Rhinitis Headache Eczema Urticaria Abdominal pain/Upper abdominal pain.

BILAGRA M tablet work by blocking effects of chemical messengers called histamine and leukotriene respectively which helps in reducing inflammation in the airways to prevent asthma and relieve symptoms of allergies.

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• alcohol consumption needs to be avoided while on BILAGRA M medication • avoid driving while on this medication as it may cause drowsiness • inform your doctor if you are pregnant or breastfeeding • consume antacid and this medication with 2 hours gap as taking these medications simultaneously may decrease absorption of bilastine and montelukast sodium tablet.

major • montelukast sodium + dasabuvir: concurrent use leads to increased dasabuvir concentration • montelukast sodium + leflunamide: concurrent use may result in increased exposure of cyp2c8 substrate • montelukast sodium + pixantrone: concurrent use leads to increased exposure of cyp2c8 substrate • montelukast sodium + teriflunomide: concurrent use lead to increased exposure of cyp2c8 substrate .